Bedrijfsoverzicht
ACADIA Pharmaceuticals Inc. is a biopharmaceutical enterprise dedicated to the research, development, and commercialization of therapeutic medicines specifically targeting neurological and rare diseases within the North American market. The company operates within the broader Healthcare sector, with its specific focus classified under the Biotechnology industry, positioning it as a specialized player in the development of selective serotonin inverse agonists/antagonists like NUPLAZID for treating hallucinations. As of the latest available data, the entity holds a market capitalization of $3.71 billion and generated annual revenue of $1.07 billion, employing a workforce of 796 individuals. These valuation and revenue figures indicate that ACADIA has established a significant footprint in the biopharmaceutical landscape, maintaining a status that reflects substantial operational scale relative to many early-stage peers, while its revenue base supports a robust cash position of $819.69 million.
Financiële gezondheid
The company reported revenue of $1.07 billion over the trailing twelve months, accompanied by a net income of $391.00 million and an EBITDA of $116.57 million, highlighting a substantial difference between top-line revenue and bottom-line earnings that reveals a high cost structure relative to gross sales. Specifically, the gap between the $1.07 billion revenue and $391.00 million net income suggests that operating expenses, including research, development, and administrative costs, absorb a significant portion of the top line before reaching the bottom line. The free cash flow stands at $-54,821,124, indicating a period where capital expenditures and working capital requirements exceed operating cash generation, which implies a need for liquidity management despite a strong cash reserve of $819.69 million. Margin analysis shows a gross margin of 61.0%, an operating margin of 6.1%, and a profit margin of 36.5%, where the high profit margin relative to the operating margin suggests significant non-operating income or specific accounting adjustments influencing the net income figure. Regarding leverage, the company holds $819.69 million in cash against total debt of $52.19 million, resulting in a debt-to-equity ratio of 4.25, which presents a complex balance sheet picture given the high equity multiplier despite the low absolute debt level. The current ratio is reported at 3.83, a metric that indicates the company possesses a highly conservative approach to short-term liquidity, with current assets significantly exceeding current liabilities. Return on Equity is 39.9% while Return on Assets is 4.8%, revealing that management is generating high returns on shareholder equity, likely driven by the company's specific capital structure, while the return on assets remains modest, reflecting the capital-intensive nature of the biotechnology industry.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is 9.45, while the forward P/E is projected at 23.63, and this significant disparity implies that the market expects earnings growth to accelerate substantially in the coming fiscal year to justify the higher forward multiple. The price-to-book ratio stands at 3.02, indicating that the market values the company at a substantial premium over its net asset book value, which often reflects the high value assigned to intellectual property and intangible assets in the biotechnology sector. Alternative valuation metrics include a price-to-sales ratio of 3.46 and an EV/EBITDA of 25.21, suggesting that investors are willing to pay a premium for revenue and adjusted earnings that are not fully captured by the standard P/E multiple. The stock has traded within a 52-week range bounded by a high of $28.35 and a low of $14.08, placing the current trading price contextually within this historical volatility band. The beta value is 0.83, which signifies that the stock's price volatility is lower than the broader market average, suggesting a defensive characteristic often found in healthcare equities that may dampen upside potential during market rallies but also provide stability during downturns.
Growth & Income
Revenue growth year-over-year is 9.4%, whereas earnings growth year-over-year is 86.2%, demonstrating that profitability is expanding at a rate far exceeding top-line revenue growth, which implies strong operational leverage or cost efficiencies are being realized as sales scale. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm retains all its earnings rather than distributing them to shareholders. This retention strategy aligns with the industry practice of reinvesting capital back into research, development, and commercial expansion to fuel future growth rather than providing immediate income to investors. Consequently, the overall profile of ACADIA Pharmaceuticals is characterized by aggressive earnings expansion relative to revenue and a capital allocation strategy focused entirely on organic growth and asset development rather than income generation.